Radiopharmaceutical Patents

Radiopharmaceutical patents cover targeting-ligand innovations; chelator and radioconjugate innovations; radioisotope and alpha-emitter innovations; and isotope-supply, radiolabeling, and theranostic-pairing innovations — with IP held by the radioligand-therapy leader, alpha-emitter pioneers, and a wave of acquired specialists. MAJOR RADIOPHARMACEUTICAL PATENT HOLDERS: NOVARTIS (the radioligand-therapy leader, via Advanced Accelerator Applications and Endocyte): Pluvicto (lutetium-177 PSMA-617, for PSMA-positive metastatic prostate cancer — a blockbuster), Lutathera (Lu-177 DOTATATE, for neuroendocrine tumors), and a deep targeting-ligand/chelator estate. BAYER: Xofigo (radium-223 dichloride, an alpha-emitter for bone-metastatic prostate cancer). The big-pharma land-grab: RAYZEBIO (Bristol Myers Squibb, actinium-225 alpha-emitter programs), FUSION PHARMACEUTICALS (AstraZeneca, targeted alpha), POINT BIOPHARMA (Eli Lilly), and Mariana (Novartis) — radiopharma was a major M&A wave. OTHERS: Telix Pharmaceuticals (PSMA imaging/therapy), Lantheus (imaging — PYLARIFY F-18 PSMA), Curium and Cardinal (isotope/manufacturing), Clarity Pharmaceuticals (copper-64/67 theranostic), and Orano/IBA (isotope supply). Targeting ligands, chelators, and (increasingly) alpha-emitters are the core radiopharmaceutical patent domains.

Targeting-ligand innovations; chelator-chemistry innovations; linker and radioconjugate-construct innovations; and pharmacokinetic-tuning innovations represent core radiopharmaceutical patent domains — and the ligand–chelator–isotope construct is the composition-of-matter that defines a radiopharmaceutical. TARGETING-LIGAND PATENTS: the molecule that binds a tumor target — PSMA-binding ligands (PSMA-617, PSMA-I&T glutamate-urea motifs for prostate), somatostatin-receptor peptides (DOTATATE/DOTATOC for neuroendocrine), FAP (fibroblast-activation-protein) inhibitors, GRPR/bombesin, integrins, and antibody/minibody/peptide targeting vehicles. CHELATOR PATENTS: the cage that holds the radiometal — DOTA (the workhorse for Lu-177/Y-90), DOTAGA, NOTA, and isotope-specific chelators like macropa or crown ethers for actinium-225 and lead-212 (matching a chelator to an alpha-emitter's coordination chemistry is a distinct, valuable problem). LINKER / CONSTRUCT PATENTS: the linker joining ligand and chelator, albumin-binding moieties to extend circulation and tumor uptake, and the overall radioconjugate as composition-of-matter. PHARMACOKINETIC PATENTS: kidney-protection and clearance modification, and dosing. The complete ligand-linker-chelator-isotope construct (and chelators matched to alpha-emitters) is the highest-value radiopharmaceutical IP because it is the drug.

Radioisotope-selection innovations; alpha-emitter innovations; isotope-production and supply-chain innovations; and theranostic-pairing and radiolabeling innovations represent additional radiopharmaceutical patent domains — and isotope supply (especially actinium-225) is a defining industry constraint. RADIOISOTOPE PATENTS: beta-emitters (lutetium-177 — the current therapeutic workhorse, yttrium-90), and the diagnostic partners (gallium-68, fluorine-18, copper-64, zirconium-89) used to image the same target before therapy. ALPHA-EMITTER PATENTS: targeted alpha therapy using actinium-225, lead-212, thorium-227, astatine-211, and radium-223 — alphas deliver far higher, very short-range cytotoxic energy (more potent, less off-target) but raise daughter-recoil and chelation challenges; alpha-emitter constructs and handling are a hot, less-crowded patent frontier. ISOTOPE-SUPPLY PATENTS: production methods for scarce isotopes — Ac-225 (from thorium-229 generators, accelerator/cyclotron, or spallation), Lu-177 (direct vs. carrier-free no-carrier-added), generator systems, and target/processing chemistry — supply is THE bottleneck for the field, so production IP is strategically valuable. RADIOLABELING / MANUFACTURING PATENTS: automated radiosynthesis modules, kit formulations (cold kits labeled on-site), and stabilization against radiolysis (short half-lives demand decentralized, just-in-time manufacturing). THERANOSTIC PATENTS: diagnostic/therapeutic pairs targeting the same receptor (image with Ga-68, treat with Lu-177). Alpha-emitter constructs and isotope-supply/production are the highest-strategic-value radiopharmaceutical IP.

Radiopharmaceutical startup IP strategy must navigate Novartis's deep PSMA/somatostatin ligand and chelator estate (Pluvicto/Lutathera), Bayer and the alpha-emitter players' patents, an intense M&A environment (big pharma acquired RayzeBio, Fusion, Point, Mariana — IP plus isotope supply drove valuations), the actinium-225/isotope supply constraint, and short-half-life decentralized-manufacturing realities; understand that the durable asset is a specific targeting-ligand–chelator–isotope construct (composition-of-matter) plus, crucially, secured isotope supply, that alpha-emitters and novel targets (FAP, beyond PSMA) are the open frontier, and that manufacturing/supply IP can be as valuable as the molecule; identify whitespace in novel targets, alpha-emitter chelators/constructs, and isotope-production methods. RADIOPHARMACEUTICAL STARTUP IP STRATEGY: THE LIGAND-CHELATOR-ISOTOPE CONSTRUCT IS THE IP — BUT ISOTOPE SUPPLY IS THE MOAT: patent the specific targeting-ligand + chelator + isotope construct as composition-of-matter, but recognize that secured/patented isotope supply (especially Ac-225) is often what makes the company investable; ALPHA-EMITTERS AND NOVEL TARGETS ARE HIGHEST-VALUE WHITESPACE: targeted alpha therapy (Ac-225, Pb-212, Th-227) and targets beyond PSMA/somatostatin (FAP, GRPR, novel receptors) are the open, M&A-attractive frontier; CHELATORS MATCHED TO ALPHA-EMITTERS ARE PATENTABLE AND HARD: actinium/lead chelation (macropa, novel cages) with daughter-recoil management is a distinct, valuable problem; ISOTOPE-PRODUCTION AND DECENTRALIZED MANUFACTURING ARE STRATEGIC IP: Ac-225/Lu-177 production methods, generators, and just-in-time radiosynthesis (short half-lives) are scarce and valuable; THERANOSTIC PAIRING IS A FEATURE: a matched diagnostic (Ga-68/F-18) plus therapeutic (Lu-177/Ac-225) strengthens the franchise; WHEN TO PATENT: NOVEL CONSTRUCT/ISOTOPE-PROCESS WITH MEASURED PERFORMANCE: file once a construct shows measured results (target affinity + tumor uptake %ID/g + tumor-to-kidney ratio + isotope purity/yield + efficacy) — measured target uptake, tumor-to-normal-tissue ratio, isotope purity/supply, and efficacy are the critical radiopharmaceutical IP metrics; KEY FTO CHECKLIST: Novartis PSMA-617/PSMA-I&T glutamate-urea, DOTATATE somatostatin, DOTA/DOTAGA chelator, Lu-177; Bayer radium-223; RayzeBio/Fusion/Point Ac-225 alpha; macropa/crown chelator for Ac-225/Pb-212; albumin-binder PK extension; Ga-68/F-18/Cu-64 diagnostic pairing; Ac-225 thorium-229-generator/accelerator supply; automated radiosynthesis cold-kit; FAP/GRPR novel targets; theranostic pairing.